How cancer's genetic and metabolic processes interact
Interaction between nuclear epigenetic and metabolic pathways in cancer
This study is looking at how certain changes in our genes and metabolism affect cancer cells, with the goal of finding new ways to treat cancer that might work better for each person.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10888233 on NIH RePORTER |
What this research studies
This research investigates the complex relationship between epigenetic mechanisms and metabolic pathways in cancer. By exploring how these pathways influence cancer cell behavior, the study aims to identify new therapeutic targets that could improve treatment outcomes. The approach involves analyzing both normal and cancer cell lines to understand the role of specific proteins, such as the tumor suppressor p53, in regulating gene expression. Patients may benefit from insights that could lead to more effective cancer therapies tailored to individual responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cancers that are resistant to current therapies or those experiencing variable responses to treatment.
Not a fit: Patients with early-stage cancers that are easily treatable with existing therapies may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve treatment effectiveness for various cancers.
How similar studies have performed: Other research has shown promising results in targeting epigenetic and metabolic pathways in cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Berger, Shelley L — University of Pennsylvania
- Study coordinator: Berger, Shelley L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.